Is This Chinese Biopharma Stock Still a Buy?
Shares in Chinese pharmaceutical company BeiGene (NASDAQ: BGNE) are up more than 34% this year, and more than 79% over the past 12 months. The company is coming off a strong first-quarter report, has two potential blockbuster cancer drugs in Brukinsa and Tislelizumab, and has lucrative collaboration projects with Novartis, Amgen, and Bristol Myers Squibb.
In short, there's plenty of fire to back up the optimistic smoke regarding the stock. The Chinese pharmaceutical industry is the second-largest in the world behind the United States, and like the U.S., an aging population in the country is driving increased sales.
Image source: Getty Images.
Source Fool.com